Zimmer Biomet Holdings, Inc. · ZBH · FY2026 Q2 · Calendar Q3 2026

Zimmer Biomet raises guidance as hip and technology demand strengthens

Zimmer Biomet's Q2 update supports a constructive operating thesis: hip, robotics, navigation, and acquired-product momentum helped management raise its outlook. The thesis remains dependent on executing the sales-force transition, converting product launches into sustained growth, and containing pricing, reimbursement, China, and supply pressures.

Why did ZBH rise 2.5% after beating EPS estimates in FY2026 Q2?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $18.25B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.07 Consensus $2.01
EPS surprise +3.0% Reported versus consensus
Reported revenue $2.18B Consensus $2.13B
Revenue surprise +2.0% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +2.5% Event window
SPY move -0.2% Same window
Abnormal move +2.7% Stock minus SPY
Volume 2.3× Versus trailing sessions
Subsequent drift +1.4% Up to 20 sessions
ZBHSPY benchmark

Ask FN2 about ZBH FY2026 Q2

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

Compared with the prior quarter, management reported stronger Q2 momentum and raised both organic revenue and adjusted EPS guidance. The current analysis also highlights early adoption of ROSA Shoulder, better-than-expected iodine-coated hip demand in Japan, and a sales-force transition ahead of schedule.

Guidance delta

Management raised full-year organic revenue growth guidance to 2.25%-3.25% and adjusted EPS guidance to $8.47-$8.59.

Key takeaways

  • Q2 sales were $2.177 billion, up 4.8% year over year and 4% on an organic constant-currency basis.
  • U.S. hip growth, technology revenue, and the Paragon 28 acquisition supported the quarter.
  • Management said the sales-force transition is ahead of schedule and highlighted ROSA Shoulder, iodine-coated hips, and the Z1 hip platform.
  • Supply constraints affect the iodine-coated hip platform, while China, pricing, reimbursement, and softer trauma demand remain watchpoints.

Management priorities

  • Execute the U.S. sales-force transition.
  • Expand iodine-coated hip availability beyond Japan and file the Monogram 510(k).
  • Advance ROSA, navigation, and new-product development, including more than 50 planned products over 36 months.
  • Commission the Costa Rica plant, expand R&D in India, and pursue selective acquisitions.

Follow ZBH with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
ZBH REVENUE earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q2 '24 estimate $2B Q2 '24 actual $2B, beat Q3 '24 estimate $2B Q3 '24 actual $2B, beat Q2 '25 estimate $2B Q2 '25 actual $2B, beat Q3 '25 estimate $2B Q3 '25 actual $2B, miss Q4 '25 estimate $2B Q4 '25 actual $2B, beat Q1 '26 estimate $2B Q1 '26 actual $2B, beat Q2 '26 estimate $2B Q2 '26 actual $2B, beat Q3 '26 estimate $2B Q3 '26 actual $2B, beat Q4 '26 estimate $2B Q1 '27 estimate $2B
Show 2 more >

Analyst Consensus ?

ConsensusHold42 ratings
Bullish1842.8%
Neutral2354.8%
Bearish12.4%

Analyst 52W Price Targets

$101.1Current
$83Low
$120.55Average
$180High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Barclays Equal Weight Equal WeightMaintainNov 9, 2026
Wells Fargo Equal Weight Equal WeightMaintainNov 5, 2026
UBS Buy BuyMaintainNov 5, 2026
RBC Capital Outperform OutperformMaintainNov 5, 2026
JP Morgan Neutral NeutralMaintainNov 5, 2026
Show 37 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $101.1. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Wells FargoLarry Biegelsen$123$101.41 +21.7%Nov 17, 2026
Stifel NicolausRick Wise$140$103.21 +38.5%Nov 16, 2026
Truist FinancialRichard Newitter$114$106.85 +12.8%Nov 5, 2026
Stifel NicolausRick Wise$125$110.15 +23.6%Nov 4, 2026
JefferiesMatthew Taylor$120$110.15 +18.7%Nov 4, 2026
See 74 more

Track every rating change on ZBH the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Historical context

All ZBH earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the ZBH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-08-05T20:12:06.730879+00:00
  2. FN2 earnings calendar · 2026-09-10T01:23:13.706414+00:00
  3. Polygon adjusted daily market bars · 2026-09-22T17:20:54.078563+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-22T17:20:54.075834+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-22. For educational purposes only; not investment advice.